Effects of Chemotherapy Clinical Trial
Official title:
Follicular and Luteal Dysfunction in Cancer Survivors
Women of late to mid reproductive age may participate in a study using novel methodology to identify subtle changes in the reproductive endocrine axis via daily urine hormone analysis, which may have important implications for reproduction and may signal reproductive senescence.
Women with a reduced follicular pool either from natural aging or previous chemotherapy, may not have any clinical signs or symptoms and traditional measures of ovarian reserve, such as basal Follicle Stimulating Hormone may be within the normal range. However, there may be alterations in the luteal or follicular phases(shortened follicular phase and luteal insufficiency) due to compromised follicle competency and alterations in the H-P-O axis. Therefore this aim uses novel methodology to identify subtle changes in the reproductive endocrine axis which may have important implications for reproduction and may signal reproductive senescence. Compared to yearly follicular measures of reproductive hormones, daily urine hormone analysis provides a more integrative assessment. Three groups of subjects will be recruited: Group 1: Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment. Group 2: healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy. Group 3: healthy, late reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility. Subjects in all groups must have regular menstrual cycles every 21-35 days, and have a uterus and both ovaries. Each participant will complete daily urinary collections for 2 menstrual cycles to assess reproductive hormones. The ultimate goal of this work is to better estimate the reproductive window, or time to menopause. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05529940 -
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
|
Phase 3 | |
Recruiting |
NCT02306837 -
Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
|
Phase 2 | |
Completed |
NCT02771470 -
Intestinal Microflora in Lung Cancer After Chemotherapy
|
Phase 1 | |
Completed |
NCT02454647 -
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
|
N/A | |
Completed |
NCT02454673 -
Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer
|
N/A | |
Completed |
NCT01432223 -
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
|
Phase 2 | |
Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
Recruiting |
NCT02555592 -
Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level
|
N/A | |
Suspended |
NCT02121405 -
Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM
|
Phase 3 | |
Recruiting |
NCT02226380 -
FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT00911352 -
Cryotherapy Intervention for Docetaxel-induced Nail Toxicities
|
Phase 2/Phase 3 | |
Completed |
NCT03840824 -
Blood Spot Self-administered Test and Assay
|
||
Active, not recruiting |
NCT01490060 -
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
|
N/A | |
Completed |
NCT02395341 -
The Longitudinal Ovarian Reserve Study
|
N/A | |
Recruiting |
NCT05268991 -
Aging and Frailty Study
|
||
Recruiting |
NCT03885388 -
Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6
|
Phase 2/Phase 3 | |
Completed |
NCT02375776 -
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
|
N/A | |
Enrolling by invitation |
NCT02074241 -
Molecular Markers of Chemosensitivity for Bladder Cancer
|
N/A | |
Completed |
NCT01143844 -
Assessing Fertility Potential in Female Cancer Survivors
|
||
Recruiting |
NCT02169388 -
Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy
|
Phase 1 |